Evidence map›Paper›PMID 29570891›Full record

ArticleHead & neck2018

Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.

Renata Ferrarotto, Robert Cardnell, Shirley Su, Lixia Diao, A Karina Eterovic, Victor Prieto, William H Morrisson, Jing Wang, Merrill S Kies, Bonnie S Glisson and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Merkel Cell Carcinoma.Biomedicines · 2021
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Renata FerrarottoDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3561-215X
Robert CardnellDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Shirley SuDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-3903-8204
Lixia DiaoDepartment of Bioinformatics, University of Texas MD Anderson Cancer Center, Houston, Texas.
A Karina EterovicDepartment of System Biology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Victor PrietoDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
William H MorrissonDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Jing WangDepartment of Bioinformatics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Merrill S KiesDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Bonnie S GlissonDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Lauren Averett ByersDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Diana BellDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · US

Funding

Therapeutic strategies for targeting PARP1 in small cell lung cancerR01CA207295 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Lauren Averett Byers · 2016 to 2026
$3.7M
NCI NIH HHS R01 CA207295
6 · The paper itself

Abstract

backgroundPatients with metastatic Merkel cell carcinoma are treated similarly to small cell lung cancer (SCLC). Poly ADP-ribose polymerase-1 (PARP1) is overexpressed in SCLC and response to PARP inhibitors have been reported in patients with SCLC. Our study explores PARP as a therapeutic target in Merkel cell carcinoma.

methodsWe evaluated PARP1 expression and Merkel cell polyomavirus (MCPyV) in 19 patients with Merkel cell carcinoma. Target exome-sequencing was performed in 14 samples. Sensitivity to olaparib was tested in 4 Merkel cell carcinoma cell lines.

resultsMost Merkel cell carcinomas (74%) express PARP1 at high levels. Mutations in DNA-damage repair genes were identified in 9 samples (64%), occurred exclusively in head neck primaries, and correlated with TP53/RB1 mutations. The TP53/RB1 mutations were more frequent in MCPyV-negative tumors. Sensitivity to olaparib was seen in the Merkel cell carcinoma line with highest PARP1 expression.

conclusionBased on PARP1 overexpression, DNA-damage repair gene mutations, platinum sensitivity, and activity of olaparib in a Merkel cell carcinoma line, clinical trials with PARP inhibitors are warranted in Merkel cell carcinoma.

Indexed as

AgedAged, 80 and overCarcinoma, Merkel CellCell Line, TumorDNA RepairExome SequencingFemaleHead and Neck NeoplasmsHumansImmunohistochemistryMaleMiddle AgedMutationPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1olaparibPARP1 protein, humanPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsRB1 protein, humanRetinoblastoma Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigasesgenomicsMerkel cell carcinomaMerkel cell polyomaviruspoly ADP-ribose polymerase (PARP)targeted therapy

Identifiers

PMID29570891
PMCPMC6105373
OpenAlexW2792557131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.